Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market By Product Type (Antioxidants, Biguanides), By Stage (Cirrhosis, Fibrosis), By Distribution Channel (Hospital Pharmacy, Drug Stores), By Disease Cause (Obesity, Heart Disease), & Region For 2024-2031
Report ID: 80482|No. of Pages: 202
Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market By Product Type (Antioxidants, Biguanides), By Stage (Cirrhosis, Fibrosis), By Distribution Channel (Hospital Pharmacy, Drug Stores), By Disease Cause (Obesity, Heart Disease), & Region For 2024-2031
Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market Valuation – 2024-2031
The rising prevalence of obesity and metabolic syndrome, which are primary risk factors for NAFLD. As lifestyle-related health issues become more common, the incidence of NAFLD is expected to escalate, thereby increasing the demand for effective therapeutic interventions. The need for non- alcoholic fatty liver disease (NAFLD) drug is surpassing USD 19.97 Billion in 2023 and reaching USD 28.08 Billion by 2031.
Additionally, growing awareness of liver health among healthcare providers and patients is leading to earlier diagnosis and treatment, further propelling market growth. These factors contribute to the increasing use of non- alcoholic fatty liver disease (NAFLD) drug in a variety of industries is expected to grow at a CAGR of 4.80% about from 2024 to 2031.
>>> Get | Download Sample Report @ –https://www.verifiedmarketresearch.com/download-sample/?rid=80482
Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market: Definition/ Overview
Non-Alcoholic Fatty Liver Disease (NAFLD) drug refers to pharmaceutical treatments specifically designed to address the accumulation of fat in the liver not caused by alcohol consumption, which can lead to inflammation, fibrosis, and potentially cirrhosis. These drugs aim to reduce liver fat content, improve liver function, and prevent the progression of the disease to more severe forms such as non-alcoholic steatohepatitis (NASH). Applications of NAFLD drugs encompass both symptomatic relief and long-term management, targeting high-risk populations, including individuals with obesity, diabetes, and metabolic syndrome. The future of the NAFLD drug market appears promising, driven by the increasing prevalence of the disease, ongoing advancements in drug development, and regulatory support for innovative therapies, with projections indicating significant growth as new treatment options become available to address this critical public health issue.
Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.
What's inside a VMR
industry report?
>>> Ask For Discount @ – https://www.verifiedmarketresearch.com/ask-for-discount/?rid=80482
Will Rising Prevalence of NAFLD is Propelling the Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market?
The rising prevalence of Non-Alcoholic Fatty Liver Disease (NAFLD) is indeed propelling the NAFLD drug market as more individuals are diagnosed with the condition, necessitating effective therapeutic interventions. Currently, it is estimated that approximately 25% of adults in the United States are affected by NAFLD, according to the Centers for Disease Control and Prevention (CDC). This statistic underscores the widespread nature of the disease, which is often associated with obesity, diabetes, and metabolic syndrome. As awareness of NAFLD increases among healthcare providers and patients, the demand for effective treatments is rising, directly influencing market growth.
Moreover, the progression of NAFLD to more severe liver conditions, such as non-alcoholic steatohepatitis (NASH) and cirrhosis, further intensifies the need for drug development. A report from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) indicates that about 20% of individuals with NAFLD may progress to NASH, increasing the urgency for effective therapies.
Will Regulatory Challenges Hamper the Growth of the Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market?
Regulatory challenges could indeed hamper the growth of the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market by complicating the drug approval process and increasing the time and cost associated with bringing new treatments to market. The stringent requirements imposed by regulatory bodies, such as the Food and Drug Administration (FDA), for clinical trials and safety evaluations can slow down the development pipeline. This is particularly significant for NAFLD, where the understanding of the disease’s pathophysiology is still evolving, making it difficult to establish clear endpoints for clinical efficacy.
Moreover, the lack of specific treatment guidelines for NAFLD can further complicate the regulatory landscape. Without established benchmarks for assessing the effectiveness of new therapies, developers may face additional hurdles in demonstrating the clinical value of their products. As a result, potential delays in regulatory approvals can discourage investment and innovation within the market, ultimately affecting the availability of effective treatments for patients suffering from NAFLD.
Category-Wise Acumens
Will Significant Traction Gain in Disposable Cirrhosis Boost the Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market?
Significant traction in the disposable cirrhosis segment is likely to boost the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market as healthcare providers increasingly recognize the need for effective management solutions for patients with advanced liver disease. With cirrhosis often resulting from untreated NAFLD, the growing prevalence of cirrhosis cases highlights an urgent demand for targeted therapies.
As disposable treatment options become more accessible and convenient, they encourage healthcare providers to adopt these solutions, leading to a higher rate of patient engagement and adherence to treatment protocols. Additionally, as advancements in drug development continue to yield innovative treatments specifically for cirrhosis associated with NAFLD, the market is expected to experience accelerated growth.
The Fibrosis segment is the fastest-growing segment, fueled by increasing awareness and early diagnosis of liver diseases.
Will Widespread Availability of Antioxidants Fuel the Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market?
The widespread availability of antioxidants is likely to fuel the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market by increasing awareness and accessibility of treatments aimed at managing oxidative stress associated with liver damage. Antioxidants, such as vitamin E and specific polyphenols, have gained attention for their potential to improve liver health and reduce inflammation.
As these products become more prevalent in both over-the-counter formulations and dietary supplements, patients are more inclined to seek them out as part of their treatment plans for NAFLD. This growing consumer interest can drive market expansion as healthcare providers increasingly recommend these options for managing the disease. Additionally, the incorporation of antioxidants into holistic treatment regimens for NAFLD can enhance overall patient outcomes, thereby fostering greater acceptance among healthcare practitioners.
The Biguanides segment, particularly the drug metformin, is the fastest-growing segment. Metformin’s increasing recognition for its potential benefits in treating NAFLD, alongside its established use in managing type 2 diabetes, is driving rapid adoption.
Gain Access into Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market Report Methodology
https://www.verifiedmarketresearch.com/select-licence/?rid=80482
Country/Region-wise
Will the Mature Market and Regulatory Environment in North America Drive the Expansion of The Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market?
The mature market and regulatory environment in North America are poised to significantly drive the expansion of the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market. The increasing prevalence of NAFLD, which affects approximately 25% of adults in the U.S., has prompted a surge in research and development activities targeting effective treatment options. According to the Centers for Disease Control and Prevention (CDC), the prevalence of obesity—one of the primary risk factors for NAFLD has risen to 42.4% among U.S. adults as of 2017-2018, highlighting a critical need for effective therapeutic interventions. This situation encourages pharmaceutical companies to invest in innovative drug development, further stimulated by the well-established regulatory framework that facilitates the approval process for new treatments, ensuring faster access to patients.
Moreover, the robust regulatory environment, governed by organizations such as the Food and Drug Administration (FDA), provides a clear pathway for drug approval and market entry. The FDA has already acknowledged the need for treatment options for NAFLD, indicating a favorable stance on clinical trials and expedited approvals for drugs targeting this condition. As a result, the investment landscape is becoming increasingly attractive, with analysts projecting that the NAFLD drug market could reach approximately $1.3 billion by 2026, driven by new drug launches and the rising focus on managing liver diseases.
Will Rapid Infrastructure Development in Asia Pacific Propel the Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market?
Rapid infrastructure development in the Asia Pacific region is expected to significantly boost the Non-Alcoholic Fatty Liver Disease (NAFLD) Drug Market. As countries in this region invest in healthcare infrastructure, including hospitals, clinics, and research facilities, the accessibility of healthcare services will improve. For instance, the World Bank projects that healthcare spending in Asia is expected to increase by approximately 6.3% annually, reaching around $1 trillion by 2025. This growth will facilitate better diagnosis and treatment of NAFLD, a condition affecting about 25% of the global population, with Asia experiencing a notable increase in prevalence due to rising obesity and sedentary lifestyles. Enhanced healthcare facilities will not only promote awareness but also support the development and distribution of effective NAFLD medications.
Additionally, rapid urbanization and increasing disposable incomes in the Asia Pacific region contribute to lifestyle changes that heighten the risk of NAFLD, further driving the demand for therapeutic interventions. The Asia Pacific region is witnessing a significant rise in lifestyle-related diseases, with obesity rates projected to rise by 38% by 2030, according to the International Diabetes Federation. This increase in obesity is a critical risk factor for NAFLD, prompting healthcare providers and pharmaceutical companies to focus more on developing targeted treatments. Moreover, supportive government initiatives, such as increased funding for healthcare programs and public awareness campaigns regarding liver health, are expected to bolster the NAFLD drug market. With these factors at play, the Asia Pacific region is poised for substantial growth in the NAFLD drug market, driven by improved infrastructure and an urgent need for effective treatment options.
Competitive Landscape
The competitive landscape of the non- alcoholic fatty liver disease (NAFLD) drug market is characterized by a mix of established players and emerging startups, each focusing on innovative features such as real-time tracking, integration with IoT devices, and user-friendly interfaces. Companies are increasingly investing in research and development to enhance product offerings and improve customer service, creating a dynamic and rapidly evolving market environment.
Some of the prominent players operating in the non- alcoholic fatty liver disease (NAFLD) drug market include:
Pfizer Inc., Takeda, Intercept Pharmaceuticals, Roche, AstraZeneca, Novartis AG, Merck & Co., Inc., AbbVie Inc., Gilead Sciences, Inc.
Latest Developments
- In August 2024 the U.S. Food and Drug Administration approved Rezdiffra (resmetirom) as the first treatment for adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring. This marks a significant breakthrough, as prior to this, there were no approved medications addressing liver damage in such patients. Rezdiffra activates a thyroid hormone receptor, reducing liver fat accumulation and has demonstrated efficacy in improving liver scarring.
- In July 2024 Following the approval of Rezdiffra, several pharmaceutical companies have ramped up their clinical trials for various NASH medications. Companies are now encouraged to explore and develop other drug candidates, as they have a clearer understanding of the efficacy benchmarks set by Rezdiffra’s approval?.
- In June 2024 Companies are exploring advanced drug delivery systems to improve the bioavailability and patient adherence of existing and new NAFLD treatments. These innovations could significantly impact treatment regimens, enhancing the effectiveness of drugs while reducing side effects.
Report Scope
| REPORT ATTRIBUTES | DETAILS |
|---|---|
| Study Period | 2018-2031 |
| Growth Rate | CAGR of ~4.80% from 2024 to 2031 |
| Base Year for Valuation | 2023 |
| Historical Period | 2018-2022 |
| Forecast Period | 2024-2031 |
| Quantitative Units | Value in USD Billion |
| Report Coverage | Historical and Forecast Revenue Forecast, Historical and Forecast Volume, Growth Factors, Trends, Competitive Landscape, Key Players, Segmentation Analysis |
| Segments Covered |
|
| Regions Covered |
|
| Key Players | Pfizer Inc., Takeda, Intercept Pharmaceuticals, Roche, AstraZeneca, Novartis AG, Merck & Co., Inc., AbbVie Inc., Gilead Sciences, Inc. |
| Customization | Report customization along with purchase available upon request |
Non- Alcoholic Fatty Liver Disease (NAFLD) Drug Market, By Category
Product Type:
- Antioxidants
- Biguanides
Stage:
- Cirrhosis
- Fibrosis
Distribution Channel:
- Hospital Pharmacy
- Drug Stores
Disease Cause:
- Obesity
- Heart Disease
Region:
- North America
- Europe
- Asia-Pacific
- South America
- Middle East & Africa
Research Methodology of Verified Market Research:
To know more about the Research Methodology and other aspects of the research study, kindly get in touch with our Sales Team at Verified Market Research.
Reasons to Purchase this Report:
• Qualitative and quantitative analysis of the market based on segmentation involving both economic as well as non-economic factors
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry with respect to recent developments (which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes an in-depth analysis of the market of various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
• In case of any Queries or Customization Requirements please connect with our sales team, who will ensure that your requirements are met.
Frequently Asked Questions
1 INTRODUCTION OF GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET
1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources
4 GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET OUTLOOK
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET, BY PRODUCT TYPE
5.1 Overview
5.2 Antioxidants
5.3 Biguanides
6 GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET, BY STAGE
6.1 Overview
6.2 Cirrhosis
6.3 Fibrosis
7 GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET, BY DISTRIBUTION CHANNEL
7.1 Overview
7.2 Hospital Pharmacy
7.3 Drug Stores
8GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET, BY DISEASE CAUSE
8.1 Obesity
8.2 Heart Disease
9 GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET, BY GEOGRAPHY
9.1 Overview
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.2.3 Mexico
9.3 Europe
9.3.1 Germany
9.3.2 U.K.
9.3.3 France
9.3.4 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Rest of Asia Pacific
9.5 Rest of the World
9.5.1 Latin America
9.5.2 Middle East & Africa
10 GLOBAL NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) DRUG MARKET COMPETITIVE LANDSCAPE
10.1 Overview
10.2 Company Market Ranking
10.3 Key Development Strategies
11 COMPANY PROFILES
11.1 Pfizer Inc
11.1.1 Overview
11.1.2 Financial Performance
11.1.3 Product Outlook
11.1.4 Key Developments
11.2 Takeda
11.2.1 Overview
11.2.2 Financial Performance
11.2.3 Product Outlook
11.2.4 Key Developments
11.3 Roche
11.3.1 Overview
11.3.2 Financial Performance
11.3.3 Product Outlook
11.3.4 Key Developments
11.4 AstraZeneca
11.4.1 Overview
11.4.2 Financial Performance
11.4.3 Product Outlook
11.4.4 Key Developments
11.5 Novartis AG
11.5.1 Overview
11.5.2 Financial Performance
11.5.3 Product Outlook
11.5.4 Key Developments
11.6 Merck & Co., Inc
11.6.1 Overview
11.6.2 Financial Performance
11.6.3 Product Outlook
11.6.4 Key Developments
11.7 AbbVie Inc
11.7.1 Overview
11.7.2 Financial Performance
11.7.3 Product Outlook
11.7.4 Key Developments
11.8 Gilead Sciences, Inc
11.8.1 Overview
11.8.2 Financial Performance
11.8.3 Product Outlook
11.8.4 Key Developments
12 Appendix
12.1 Related Research
Report Research Methodology
Verified Market Research uses the latest researching tools to offer accurate data insights. Our experts deliver the best research reports that have revenue generating recommendations. Analysts carry out extensive research using both top-down and bottom up methods. This helps in exploring the market from different dimensions.
This additionally supports the market researchers in segmenting different segments of the market for analysing them individually.
We appoint data triangulation strategies to explore different areas of the market. This way, we ensure that all our clients get reliable insights associated with the market. Different elements of research methodology appointed by our experts include:
Exploratory data mining
Market is filled with data. All the data is collected in raw format that undergoes a strict filtering system to ensure that only the required data is left behind. The leftover data is properly validated and its authenticity (of source) is checked before using it further. We also collect and mix the data from our previous market research reports.
All the previous reports are stored in our large in-house data repository. Also, the experts gather reliable information from the paid databases.
For understanding the entire market landscape, we need to get details about the past and ongoing trends also. To achieve this, we collect data from different members of the market (distributors and suppliers) along with government websites.
Last piece of the ‘market research’ puzzle is done by going through the data collected from questionnaires, journals and surveys. VMR analysts also give emphasis to different industry dynamics such as market drivers, restraints and monetary trends. As a result, the final set of collected data is a combination of different forms of raw statistics. All of this data is carved into usable information by putting it through authentication procedures and by using best in-class cross-validation techniques.
Data Collection Matrix
| Perspective | Primary Research | Secondary Research |
|---|---|---|
| Supplier side |
|
|
| Demand side |
|
|
Econometrics and data visualization model
Our analysts offer market evaluations and forecasts using the industry-first simulation models. They utilize the BI-enabled dashboard to deliver real-time market statistics. With the help of embedded analytics, the clients can get details associated with brand analysis. They can also use the online reporting software to understand the different key performance indicators.
All the research models are customized to the prerequisites shared by the global clients.
The collected data includes market dynamics, technology landscape, application development and pricing trends. All of this is fed to the research model which then churns out the relevant data for market study.
Our market research experts offer both short-term (econometric models) and long-term analysis (technology market model) of the market in the same report. This way, the clients can achieve all their goals along with jumping on the emerging opportunities. Technological advancements, new product launches and money flow of the market is compared in different cases to showcase their impacts over the forecasted period.
Analysts use correlation, regression and time series analysis to deliver reliable business insights. Our experienced team of professionals diffuse the technology landscape, regulatory frameworks, economic outlook and business principles to share the details of external factors on the market under investigation.
Different demographics are analyzed individually to give appropriate details about the market. After this, all the region-wise data is joined together to serve the clients with glo-cal perspective. We ensure that all the data is accurate and all the actionable recommendations can be achieved in record time. We work with our clients in every step of the work, from exploring the market to implementing business plans. We largely focus on the following parameters for forecasting about the market under lens:
- Market drivers and restraints, along with their current and expected impact
- Raw material scenario and supply v/s price trends
- Regulatory scenario and expected developments
- Current capacity and expected capacity additions up to 2027
We assign different weights to the above parameters. This way, we are empowered to quantify their impact on the market’s momentum. Further, it helps us in delivering the evidence related to market growth rates.
Primary validation
The last step of the report making revolves around forecasting of the market. Exhaustive interviews of the industry experts and decision makers of the esteemed organizations are taken to validate the findings of our experts.
The assumptions that are made to obtain the statistics and data elements are cross-checked by interviewing managers over F2F discussions as well as over phone calls.
Different members of the market’s value chain such as suppliers, distributors, vendors and end consumers are also approached to deliver an unbiased market picture. All the interviews are conducted across the globe. There is no language barrier due to our experienced and multi-lingual team of professionals. Interviews have the capability to offer critical insights about the market. Current business scenarios and future market expectations escalate the quality of our five-star rated market research reports. Our highly trained team use the primary research with Key Industry Participants (KIPs) for validating the market forecasts:
- Established market players
- Raw data suppliers
- Network participants such as distributors
- End consumers
The aims of doing primary research are:
- Verifying the collected data in terms of accuracy and reliability.
- To understand the ongoing market trends and to foresee the future market growth patterns.
Industry Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|---|---|
|
|
